Johnson & Johnson Vaccine Usage Halted Due to Rare Blood Clots

CDC Principal Deputy Director Dr. Anne Sccuchat and FDC Director for Biologics Evaluation and Research Peter Marks expelled a matter job for a Johnson Johnson (Janssen) vaccine administration to be paused as of Apr 13, 2021.

They done this integrity out of an contentment of counsel after 6 cases of a singular and serious form of blood clot were reported.

“In these cases, a form of clot is called intelligent venous sinus thrombosis (CVST) was seen in multiple with low levels of blood platelets (thrombocytopenia).

Those influenced with these singular clots were women between 18 to 48; symptoms occurred 6 to 13 days after they were vaccinated.

The CDC is formulation to call a assembly for a Advisory Committee on Immunization Practices (ACIP) on Wednesday, Apr 14. The cabinet will serve examination a cases and establish their intensity significance. The FDA will examination a CDC’s research while it also investigates these cases.

At this time, these 6 inauspicious reports seem to be intensely rare. As of Apr 12, over 6.8 million doses of a Johnson Johnson vaccine have been administered in a United States.

COVID-19 vaccine reserve is a tip priority for a CDC and FDA, and all reports of inauspicious reactions are delicately reviewed.

Those who have perceived a Johnson Johnson Janssen vaccine who rise a serious headache, leg or abdominal pain, or knowledge crispness of exhale within 3 weeks after inoculation should hit a devoted health caring provider.

The CDC and FDA ask health caring providers to record a news on a HHS website: Vaccine Adverse Event Reporting System.¹.

Written by Cathy Milne-Ware

Source:

CDC: Joint CDC and FDA Statement on Johnson Johnson COVID-19 Vaccine
Link: ¹https://vaers.hhs.gov/reportevent.html

Images by Sgt. Sebastian Rothwyn Courtesy of New York National Guard’s Flickr Page – Creative Commons License

  #CMJournalist, cdc, intelligent venous sinus thrombosis, FDA, spot, Vaccine